Diethylpropion Hydrochloride Er
Loading...Diethylpropion Hydrochloride Er Recall
Get an alert when a recall is issued.
Questions & Answers
Side Effects & Adverse Reactions
Diethylpropion hydrochloride extended release tablets, 75 mg should not be used in combination with other anorectic agents, including prescribed drugs, over-the-counter preparations, and herbal products.
In a case-control epidemiological study, the use of anorectic agents, including diethylpropion, was associated with an increased risk of developing pulmonary hypertension, a rare, but often fatal disorder. The use of anorectic agents for longer than 3 months was associated with a 23-fold increase in the risk of developing pulmonary hypertension. Increased risk of pulmonary hypertension with repeated courses of therapy cannot be excluded.
The onset or aggravation of exertional dyspnea, or unexplained symptoms of angina pectoris, syncope, or lower extremity edema suggest the possibility of occurrence of pulmonary hypertension. Under these circumstances, diethylpropion hydrochloride extended release tablets, 75 mg should be immediately discontinued, and the patient should be evaluated for the possible presence of pulmonary hypertension.
Valvular heart disease associated with the use of some anorectic agents such as fenfluramine and dexfenfluramine has been reported. Possible contributing factors include use for extended periods of time, higher than recommended dose, and/or use in combination with other anorectic drugs. Valvulopathy has been very rarely reported with diethylpropion hydrochloride extended release tablets, 75 mg monotherapy, but the causal relationship remains uncertain. The potential risk of possible serious adverse effects such as valvular heart disease and pulmonary hypertension should be assessed carefully against the potential benefit of weight loss. Baseline cardiac evaluation should be considered to detect preexisting valvular heart diseases or pulmonary hypertension prior to initiation of diethylpropion hydrochloride extended release tablets, 75 mg treatment. Diethylpropion hydrochloride extended release tablets, 75 mg are not recommended in patients with known heart murmur or valvular heart disease. Echocardiogram during and after treatment could be useful for detecting any valvular disorders which may occur.
To limit unwarranted exposure and risks, treatment with diethylpropion hydrochloride extended release tablets, 75 mg should be continued only if the patient has satisfactory weight loss within the first 4 weeks of treatment (e.g., weight loss of at least 4 pounds, or as determined by the physician and patient).
Diethylpropion hydrochloride extended release tablets, 75 mg are not recommended for patients who used any anorectic agents within the prior year.
If tolerance develops, the recommended dose should not be exceeded in an attempt to increase the effect; rather, the drug should be discontinued. Diethylpropion hydrochloride extended release tablets, 75 mg may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle; the patient should therefore be cautioned accordingly.
Prolonged use of diethylpropion hydrochloride may induce dependence with withdrawal syndrome on cessation of therapy. Hallucinations have occurred rarely following high doses of the drug. Several cases of toxic psychosis have been reported following the excessive use of the drug and some have been reported in which the recommended dose appears not to have been exceeded. Psychosis abated after the drug was discontinued. When central nervous system active agents are used, consideration must always be given to the possibility of adverse interactions with alcohol.
Legal Issues
There is currently no legal information available for this drug.
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
Manufacturer Warnings
There is currently no manufacturer warning information available for this drug.
FDA Labeling Changes
There are currently no FDA labeling changes available for this drug.
Uses
Diethylpropion hydrochloride extended release tablets, 75 mg are indicated in the management of exogenous obesity as a short-term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction in patients with an initial body mass index (BMI) of 30 kg/m2 or higher and who have not responded to appropriate weight reducing regimen (diet and/or exercise) alone. Below is a chart of BMI based on various heights and weights. BMI is calculated by taking the patient’s weight, in kilograms (kg), divided by the patient’s height, in meters (m), squared. Metric conversions are as follows: pounds divided by 2.2 = kg; inches x 0.0254 = meters.
| Body Mass Index (BMI), kg/m2 |
||||||
| Weight |
Height (feet, inches) |
|||||
| 5’0” |
5’3” |
5’6” |
5’9” |
6’0” |
6’3” |
|
| 140 |
27 |
25 |
23 |
21 |
19 |
18 |
| 150 |
29 |
27 |
24 |
22 |
20 |
19 |
| 160 |
31 |
28 |
26 |
24 |
22 |
20 |
| 170 |
33 |
30 |
28 |
25 |
23 |
21 |
| 180 |
35 |
32 |
29 |
27 |
25 |
23 |
| 190 |
37 |
34 |
31 |
28 |
26 |
24 |
| 200 |
39 |
36 |
32 |
30 |
27 |
25 |
| 210 |
41 |
37 |
34 |
31 |
29 |
26 |
| 220 |
43 |
39 |
36 |
33 |
30 |
28 |
| 230 |
45 |
41 |
37 |
34 |
31 |
29 |
| 240 |
47 |
43 |
39 |
36 |
33 |
30 |
| 250 |
49 |
44 |
40 |
37 |
34 |
31 |
The usefulness of agents of this class (see CLINICAL PHARMACOLOGY) should be measured against possible risk factors inherent in their use such as those described below. Diethylpropion hydrochloride extended release tablets, 75 mg are indicated for use as monotherapy only.
History
There is currently no drug history available for this drug.
Other Information
Diethylpropion Hydrochloride Extended Release Tablets, 75 mg are available for oral administration as extended release tablets containing 75 mg diethylpropion hydrochloride, USP. The inactive ingredients in each extended release tablet are: mannitol, carbomer homopolymer, tartaric acid, hydroxypropyl methylcellulose, povidone, and magnesium stearate.
Diethylpropion hydrochloride is a sympathomimetic agent. The chemical name for diethylpropion hydrochloride is 1-phenyl-2-diethyl-amino-1-propanone hydrochloride.
Its chemical structure is:
In diethylpropion hydrochloride extended release tablets, 75 mg, diethylpropion hydrochloride is dispersed in a hydrophilic matrix. On exposure to water, the diethylpropion hydrochloride is released at a relatively uniform rate as a result of slow hydration of the matrix. The result is controlled release of the anorectic agent.
Sources
Diethylpropion Hydrochloride Er Manufacturers
-
A-s Medication Solutions Llc
![Diethylpropion Hydrochloride Er (Diethylpropion Hydrochloride) Tablet, Extended Release [A-s Medication Solutions Llc]](/wp-content/themes/bootstrap/assets/img/loading2.gif)
Diethylpropion Hydrochloride Er | A-s Medication Solutions Llc
Diethylpropion Hydrochloride Extended Release Tablets, 75 mg:
One extended-release 75 mg tablet daily, swallowed whole, in midmorning.
Geriatric use
This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. (See PRECAUTIONS, Geriatric Use.)
-
Lannett Company, Inc.
Diethylpropion Hydrochloride Er | Lannett Company, Inc.
Diethylpropion Hydrochloride Extended Release Tablets, 75 mg:
One extended-release 75 mg tablet daily, swallowed whole, in midmorning.
Geriatric use
This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. (See PRECAUTIONS, Geriatric Use.)
-
Preferred Pharmaceuticals, Inc.
Diethylpropion Hydrochloride Er | Preferred Pharmaceuticals, Inc.
Diethylpropion Hydrochloride Extended Release Tablets, 75 mg:
One extended-release 75 mg tablet daily, swallowed whole, in midmorning.
Geriatric use
This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. (See PRECAUTIONS, Geriatric Use.)
-
Pd-rx Pharmaceuticals, Inc.
Diethylpropion Hydrochloride Er | Pd-rx Pharmaceuticals, Inc.
Diethylpropion Hydrochloride Extended Release Tablets, 75 mg:
One extended-release 75 mg tablet daily, swallowed whole, in midmorning.
Geriatric use
This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. (See PRECAUTIONS, Geriatric Use.)
![Diethylpropion Hydrochloride Er (Diethylpropion Hydrochloride) Tablet, Extended Release [Lannett Company, Inc.]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=dab53f4f-68d4-4477-a2b6-ad44a956332b&name=diethylpropion-hydrochloride-extended-release-tabl-2.jpg)
![Diethylpropion Hydrochloride Er (Diethylpropion Hydrochloride) Tablet, Extended Release [Preferred Pharmaceuticals, Inc.]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4bf6ac3d-78e9-4110-809b-791a36c11622&name=4bf6ac3d-78e9-4110-809b-791a36c11622-02.jpg)
![Diethylpropion Hydrochloride Er (Diethylpropion Hydrochloride) Tablet, Extended Release [Pd-rx Pharmaceuticals, Inc.]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0d213a24-ebbf-41df-8f32-de44a572829e&name=43063532.jpg)
Login To Your Free Account